V Wealth Management LLC raised its position in Amgen, Inc. (NASDAQ:AMGN) by 3.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 14,480 shares of the medical research company’s stock after acquiring an additional 501 shares during the quarter. Amgen makes up about 1.4% of V Wealth Management LLC’s holdings, making the stock its 15th largest holding. V Wealth Management LLC’s holdings in Amgen were worth $2,684,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Janus Henderson Group PLC boosted its position in shares of Amgen by 3,664.7% during the 2nd quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock worth $637,139,000 after purchasing an additional 3,601,087 shares in the last quarter. FMR LLC boosted its position in shares of Amgen by 4.8% during the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after purchasing an additional 2,587,041 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Amgen by 40.9% during the 2nd quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock worth $585,607,000 after purchasing an additional 986,700 shares in the last quarter. BlackRock Inc. boosted its position in shares of Amgen by 1.9% during the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after purchasing an additional 909,689 shares in the last quarter. Finally, Nordea Investment Management AB boosted its position in shares of Amgen by 12.9% during the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after purchasing an additional 806,119 shares in the last quarter. 78.03% of the stock is currently owned by institutional investors.
AMGN has been the topic of several research analyst reports. Piper Jaffray Companies restated a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Mizuho set a $192.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Thursday, December 28th. Oppenheimer restated a “buy” rating and set a $205.00 target price on shares of Amgen in a research report on Thursday, November 30th. Cann restated a “buy” rating and set a $205.00 target price on shares of Amgen in a research report on Thursday, November 30th. Finally, Goldman Sachs Group lowered shares of Amgen from a “conviction-buy” rating to a “buy” rating in a research report on Friday, December 15th. Sixteen research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Amgen currently has an average rating of “Hold” and an average target price of $191.84.
Amgen, Inc. (AMGN) opened at $186.67 on Friday. The stock has a market cap of $134,507.31, a PE ratio of 14.84, a price-to-earnings-growth ratio of 2.23 and a beta of 1.42. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35. Amgen, Inc. has a 1-year low of $152.16 and a 1-year high of $201.23.
Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. Amgen’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter last year, the company posted $2.89 earnings per share. equities research analysts predict that Amgen, Inc. will post 13.21 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be issued a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 2.83%. This is a positive change from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s dividend payout ratio is 205.45%.
Amgen declared that its board has initiated a share buyback plan on Thursday, February 1st that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its shares are undervalued.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total value of $283,070.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 4,575 shares of company stock worth $818,361. 0.19% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “V Wealth Management LLC Purchases 501 Shares of Amgen, Inc. (AMGN)” was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://transcriptdaily.com/2018/02/25/v-wealth-management-llc-purchases-501-shares-of-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.